{"success":true,"data":{"pressRelease":{"id":"17692","rtpr_id":"nACSgx7zZa","ticker":"IBRX","exchange":"NASDAQ","all_tickers":["IBRX"],"title":"Pomerantz LLP Issues Alert Regarding Shareholder Class Action Against ImmunityBio, Inc. – IBRX","author":"ACCESSWIRE","published_at":"2026-05-01T22:00:02.591Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst ImmunityBio, Inc. (\"ImmunityBio\" or the \"Company\")\n(NASDAQ:IBRX).   Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980.\nThose who inquire by e-mail are encouraged to include their mailing address,\ntelephone number, and the number of shares purchased.\n\nThe class action concerns whether ImmunityBio and certain of its officers\nand/or directors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have until May 26, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired ImmunityBio securities\nduring the Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/learn-more-form?company=IBRX)\n\nOn March 24, 2026, a warning letter to ImmunityBio from the U.S. Food and Drug\nAdministration (\"FDA\"), dated March 13, 2026, became public. In the letter,\nthe FDA asserted that, despite previous warnings from the FDA about the\naccuracy of the Company's promotions, \"ImmunityBio continues to promote\nAnktiva\"-the Company's bladder-cancer drug-\"in a similar misleading manner\",\nincluding in television advertisements and on a January episode of Sean\nSpicer's podcast.\n\nOn this news, ImmunityBio's stock price fell $1.99 per share, or 21.12%, to\nclose at $7.41 per share on March 24, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-issues-alert-regarding-shareholder-class-action-ag-1153772)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSgx7zZa","title":"Pomerantz LLP Issues Alert Regarding Shareholder Class Action Against ImmunityBio, Inc. – IBRX","author":"ACCESSWIRE","ticker":"IBRX","created":"2026-05-01T22:00:02.591Z","tickers":["IBRX"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst ImmunityBio, Inc. (\"ImmunityBio\" or the \"Company\")\n(NASDAQ:IBRX).   Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980.\nThose who inquire by e-mail are encouraged to include their mailing address,\ntelephone number, and the number of shares purchased.\n\nThe class action concerns whether ImmunityBio and certain of its officers\nand/or directors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have until May 26, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired ImmunityBio securities\nduring the Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/learn-more-form?company=IBRX)\n\nOn March 24, 2026, a warning letter to ImmunityBio from the U.S. Food and Drug\nAdministration (\"FDA\"), dated March 13, 2026, became public. In the letter,\nthe FDA asserted that, despite previous warnings from the FDA about the\naccuracy of the Company's promotions, \"ImmunityBio continues to promote\nAnktiva\"-the Company's bladder-cancer drug-\"in a similar misleading manner\",\nincluding in television advertisements and on a January episode of Sean\nSpicer's podcast.\n\nOn this news, ImmunityBio's stock price fell $1.99 per share, or 21.12%, to\nclose at $7.41 per share on March 24, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-issues-alert-regarding-shareholder-class-action-ag-1153772)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T22:00:02.647356787Z","server_sent_at_ms":1777672802647},"received_at":"2026-05-01T22:00:02.698Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-issues-alert-regarding-shareholder-class-action-ag-1153772"},"analysis":{"id":"12953","press_release_id":"17692","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Law-firm solicitation regarding previous FDA warning letter","Stock dropped 21.12% on prior FDA news"],"eventType":"legal_litigation","narrative":"Pomerantz LLP issued a solicitation alert regarding a class action lawsuit against ImmunityBio concerning potential securities fraud related to the promotion of its drug Anktiva.\n\nThe firm notes a March 24, 2026 FDA warning letter regarding misleading promotions, which previously caused the stock to drop 21.12%.\n\nShareholders have until May 26, 2026 to seek appointment as lead plaintiff; this release is a law-firm announcement and not an issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation based on prior FDA news -- suppress."},"keyFigures":{"customDimensions":{"stock_drop_percentage":"21.12%","lead_plaintiff_deadline":"May 26, 2026"}},"quotedText":"ImmunityBio continues to promote Anktiva-the Company's bladder-cancer drug-in a similar misleading manner","namedEntities":{"people":[{"name":"Danielle Peyton","role":"Contact"},{"name":"Sean Spicer","role":"Podcast Host"}],"products":["Anktiva"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX","relationship":"target"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$1.99","context":"per share stock price drop"},{"amount":"$7.41","context":"closing price per share on March 24, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Pomerantz LLP. The release is a standard lead-plaintiff deadline reminder and investigates claims regarding a previously disclosed FDA warning letter. No new material information or court certification is announced by the issuer."},"tickerRelevance":{"others":[],"primary":"IBRX"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","recycledNews":true,"issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz LLP issued a solicitation alert regarding a class action lawsuit against ImmunityBio concerning potential securities fraud related to the promotion of its drug Anktiva.\n\nThe firm notes a March 24, 2026 FDA warning letter regarding misleading promotions, which previously caused the stock to drop 21.12%.\n\nShareholders have until May 26, 2026 to seek appointment as lead plaintiff; this release is a law-firm announcement and not an issuer disclosure.","key_figures":{"customDimensions":{"stock_drop_percentage":"21.12%","lead_plaintiff_deadline":"May 26, 2026"}},"named_entities":{"people":[{"name":"Danielle Peyton","role":"Contact"},{"name":"Sean Spicer","role":"Podcast Host"}],"products":["Anktiva"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX","relationship":"target"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$1.99","context":"per share stock price drop"},{"amount":"$7.41","context":"closing price per share on March 24, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-01T22:10:45.056Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"law-firm-solicitation","recycledNews":true,"issuerAuthored":false}},"durationMs":44233,"modelName":"glm-4.7"}}